HPV L1病毒样颗粒疫苗诱导机体免疫反应的研究现状

Research Situation of Immunereaction Induced by Human Papillomavirus L1 Virus-like Particle Vaccine

HPV感染与宫颈癌发展密切相关,HPV病毒样颗粒(VLP)在体外由病毒的主要衣壳蛋白L1自发装配而成。HPV VLP成为候选疫苗,它能很有效的减少感染并且诱导很强的抗病毒免疫。免疫后产生的中和抗体具有型特异性,接种VLP后也能产生细胞免疫,疫苗可诱导出至少持续5年的高滴度抗L1VLP抗体,比自然感染高10倍。疫苗诱导的长期保护效应通常是免疫记忆的特征。

A persistent infection with human papillomavirus （HPV） is a prerequisite for the development of cervical cancer. HPV L1 virus-like particles （HPV） can be generated by the synthesis and self-assembly in vitro of the major virus capsid protein L1. HPV VLP are candidate vaccines that have shown to be efficacious in reducing infection and inducing robust antiviral immunity. Neutralizing antibodies generated by vaccination are largely type-specific, it also can induce cellular immune responses to VLP vaccination. The vaccines elicit high titres of anti-L1 VLP antibodies that persist at levels 10 times that of natural infections for at least 60 months, Vaccines that induce long-term protection are usually characterized by the generation of immune memory.